DALLAS, Aug. 18, 2026 — The American Heart Association has opened applications for its 2026 Health Tech Competition, a global initiative designed to move clinically promising technologies from pilot projects and startup laboratories into everyday cardiovascular and brain health care. The competition is aimed at emerging companies developing market-ready solutions in digital health, artificial intelligence, remote patient monitoring and related fields. Its central premise is that technological novelty alone is not enough: innovations must also demonstrate clinical value, operate within real health care environments and offer a credible path toward adoption by patients, clinicians and health systems.
Hosted by the American Heart Association Center for Technology & Innovation, the competition seeks technologies capable of changing how conditions such as high blood pressure, stroke and heart failure are prevented, detected and treated. The program is positioned at the intersection of biomedical research, clinical medicine, data science and health-system operations. By connecting innovators with clinicians, researchers and investors, the Association aims to shorten the distance between a validated prototype and a tool that can be deployed at scale, particularly in communities where limited access, workforce shortages and rising costs continue to delay care.
The need for scalable cardiovascular technologies is underscored by the global burden of disease. Cardiovascular disease remains the leading cause of death worldwide, while health systems are confronting increasing demand for care and persistent shortages of trained personnel. Digital tools can help address those pressures by collecting physiological data outside conventional clinics, identifying risk patterns earlier and supporting clinicians with continuously updated information. Remote monitoring devices, for example, can transmit blood pressure, heart-rate or other patient measurements for analysis between visits. Artificial intelligence systems may then detect trends or abnormalities, although their clinical usefulness depends on the quality of the data, the reliability of the algorithms and the ability of medical teams to act on the results.
Five finalists will present their technologies at Scientific Sessions 2026, the American Heart Association’s flagship international meeting for cardiovascular science and clinical advancement. The event will take place Nov. 6–9 at McCormick Place in Chicago, with the finalists scheduled to deliver live pitches Nov. 7–8. The winner will be announced Nov. 9. Before reaching the stage, applicants will be evaluated on the maturity of their technology, the strength of available clinical or pilot data, the viability of their business model and the potential to improve outcomes across different care settings. Applications remain open through Sept. 18, and the five finalists are scheduled to be announced Oct. 10.
The competition’s emphasis on clinical validation distinguishes it from many startup contests that focus primarily on technical novelty, investment potential or rapid market growth. A health technology intended for cardiovascular care must function within complex clinical workflows, where decisions can have immediate consequences. Developers may need to demonstrate that a system produces accurate measurements, limits false alarms, protects patient information and performs consistently across different populations and devices. They must also show how clinicians will interpret its outputs, how patients will be engaged and how the technology can integrate with electronic health records, telehealth platforms or existing monitoring systems without creating additional burdens for already strained care teams.
Artificial intelligence is likely to be an important component of many emerging health technologies, but the Association’s criteria reflect the growing recognition that algorithmic performance must be evaluated in context. A model that performs well in a controlled dataset may behave differently when exposed to incomplete records, inconsistent measurements or populations that were underrepresented during development. Clinical validation can reveal whether an algorithm improves diagnosis, treatment selection, adherence or patient outcomes rather than merely predicting a condition. For cardiovascular and brain health applications, the most meaningful evidence may include reductions in hospitalizations, faster treatment after stroke, improved blood-pressure control or earlier identification of heart failure deterioration.
“For more than a century, the American Heart Association has been at the intersection of science, research, clinical expertise and innovation to drive improvements in cardiovascular and brain health,” said Nancy Brown, chief executive officer of the American Heart Association. “Through the Health Tech Competition, we continue that work by helping advance evidence-based solutions that address today’s most pressing health challenges and reach people where they live, work and receive care.” The statement reflects the program’s focus on extending care beyond hospitals and specialist offices. Technologies that can support patients at home, in workplaces or in under-resourced communities may be especially important when transportation, cost or geography limits access to traditional services.
The competition is also part of the Health Innovation Pavilion at Scientific Sessions, where scientific findings, clinical tools and commercial technologies will converge before an audience of researchers, physicians, entrepreneurs and investors. That setting gives finalists an opportunity to explain not only what their products do, but also how they were tested and how they could be incorporated into routine care. A successful system might combine wearable sensors, mobile applications, cloud-based analytics and clinician dashboards, but each component must contribute to a clear clinical objective. The value of a connected platform is ultimately measured not by the volume of data it generates, but by whether that information leads to earlier intervention, better decisions or healthier lives.
Previous Association programming has highlighted the growing global appetite for health technologies that can improve heart and brain health. The organization has recognized innovators working to address unmet clinical needs and has used its competition platform to bring young companies into contact with potential partners. By emphasizing evidence-based care, the 2026 program seeks to encourage responsible commercialization rather than the rapid deployment of unproven tools. This approach may also help investors and health systems distinguish between technologies that merely promise disruption and those with measurable clinical, operational or public-health benefits.
Applications and the full terms and conditions for the 2026 Health Tech Competition are available through the American Heart Association’s Center for Technology & Innovation. The finalists’ appearance at Scientific Sessions will offer a public test of how effectively emerging companies can translate technical innovation into practical care. As artificial intelligence, connected devices and remote monitoring become increasingly embedded in medicine, the competition illustrates a broader shift in health technology: the decisive question is no longer whether a system can generate sophisticated data, but whether it can produce trustworthy evidence and deliver meaningful improvements for patients with cardiovascular and brain conditions.
Subject of Research:
Health technology innovation, artificial intelligence, digital health, remote patient monitoring, cardiovascular disease and brain health.
Article Title:
American Heart Association Opens 2026 Health Tech Competition to Accelerate Cardiovascular and Brain Health Innovation
News Publication Date:
August 18, 2026
Web References:
https://ahahealthtech.org/aha-health-tech-competition-2026/
https://ahahealthtech.org/
https://professional.heart.org/en/meetings/scientific-sessions
https://newsroom.heart.org/news/houston-based-medical-technology-company-wins-overall-global-health-tech-competition-at-scientific-sessions-2025
https://newsroom.heart.org/news/finalists-named-in-global-health-technology-competition-to-advance-heart-and-brain-health
References:
Fahim YA, Hasani IW, Kabba S, Ragab WM. “Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives.” European Journal of Medical Research. 2025;30(1):848. doi:10.1186/s40001-025-03196-w. PMID: 40988064; PMCID: PMC12455834. https://pubmed.ncbi.nlm.nih.gov/40988064/
Keywords:
American Heart Association, Health Tech Competition 2026, cardiovascular health, brain health, artificial intelligence, digital health, remote patient monitoring, health innovation, clinical validation, stroke, heart failure, hypertension, Scientific Sessions 2026, medical technology, health care technology.
Tags: artificial intelligence in healthcarebrain health technology developmentcardiovascular disease preventioncardiovascular health innovationclinical validation of health techdigital health solutions for heart diseaseglobal health technology competitionhealth system integration of digital toolshealthcare equity and access solutionsremote patient monitoring technologiesscalable medical devices for cardiovascular carestartup healthcare innovation
